# LIVMARLI® (maralixibat) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/maralixibat

> The FDA approved LIVMARLI® (maralixibat), sponsored by Mirum Pharmaceuticals, Inc. (MIRM), on April 10, 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | LIVMARLI® (maralixibat) |
| Codes | TAK-625 |
| Sponsor | Mirum Pharmaceuticals, Inc. (MIRM) https://sec-api.dev/companies/mirm/catalysts |
| Indications | [Intrahepatic Cholestasis of Pregnancy](https://sec-api.dev/indications/intrahepatic-cholestasis-of-pregnancy), Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC) |
| Modality |  |
| FDA designations | breakthrough, orphan, priority review |

## Timeline

### September 29, 2021: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA214662 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20210929, review_priority PRIORITY; sponsor_name MIRUM; product LIVMARLI (MARALIXIBAT CHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214662%22

### March 13, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA214662 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20230313, review_priority PRIORITY; sponsor_name MIRUM; product LIVMARLI (MARALIXIBAT CHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214662%22

### March 13, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA214662 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20240313, review_priority STANDARD; sponsor_name MIRUM; product LIVMARLI (MARALIXIBAT CHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214662%22

### July 24, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA214662 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20240724, review_priority STANDARD; sponsor_name MIRUM; product LIVMARLI (MARALIXIBAT CHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214662%22

### April 10, 2025: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA219485 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20250410, review_priority STANDARD; sponsor_name MIRUM; product LIVMARLI (MARALIXIBAT CHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA219485%22

### July 29, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06553768 (Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-07-29 (ACTUAL); Lead Sponsor Mirum Pharmaceuticals, Inc.." https://clinicaltrials.gov/study/NCT06553768

### Q4 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2026-01-12, last confirmed 2026-08-05.
- Press release filed with the SEC (EX-99) (accession 0001759425-26-000044): "•LIVMARLI EXPAND Phase 3 study in cholestatic pruritus due to additional rare cholestatic conditions topline results expected in Q4 2026." https://www.sec.gov/Archives/edgar/data/1759425/000175942526000044/mirm-20260805xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001759425-26-000036): "•Completed enrollment in LIVMARLI (maralixibat) EXPAND Phase 3 study in additional rare cholestatic conditions; topline results expected in Q4 2026." https://www.sec.gov/Archives/edgar/data/1759425/000175942526000036/mirm-20260506xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001759425-26-000010): "•LIVMARLI EXPAND Phase 3 study for pruritus in additional rare cholestatic conditions expected to complete enrollment H1 2026; topline data expected in Q4 2026." https://www.sec.gov/Archives/edgar/data/1759425/000175942526000010/mirm-20260225xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001759425-26-000004): "•Accelerated study timing for LIVMARLI EXPAND Phase 3 study for pruritus in rare cholestatic conditions; now expected to complete enrollment H1 2026, topline data expected in Q4 2026" https://www.sec.gov/Archives/edgar/data/1759425/000175942526000004/mirm-20260112xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001759425-26-000010): "-LIVMARLI® EXPAND study in additional cholestatic pruritus settings topline data expected Q4 2026" https://www.sec.gov/Archives/edgar/data/1759425/000175942526000010/mirm-20260225xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001759425-26-000004): "-LIVMARLI® EXPAND study in additional cholestatic pruritus settings timing accelerated; topline data now expected Q4 2026" https://www.sec.gov/Archives/edgar/data/1759425/000175942526000004/mirm-20260112xexx991.htm

### Q1 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2025-11-04, last confirmed 2026-05-06.
- Press release filed with the SEC (EX-99) (accession 0001759425-26-000036): "•VANTAGE study in primary biliary cholangitis (PBC) topline results now expected in Q1 2027." https://www.sec.gov/Archives/edgar/data/1759425/000175942526000036/mirm-20260506xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001759425-25-000053): "•LIVMARLI EXPAND Phase 3 study for pruritus in rare cholestatic conditions expected to complete enrollment in 2026; topline data expected in the first half of 2027." https://www.sec.gov/Archives/edgar/data/1759425/000175942525000053/mirm-20251104xexx991.htm
- SEC Form 10-Q (accession 0001759425-25-000054): "We expect to complete enrollment of the EXPAND study in 2026 with topline data expected in the first half of 2027." https://www.sec.gov/Archives/edgar/data/1759425/000175942525000054/mirm-20250930.htm

### Jan to Apr 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Intrahepatic Cholestasis of Pregnancy.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07823127 (MRX-901: An Open-label Study to Assess Safety and Tolerability of Maralixibat in Participants With Intrahepatic Cholestasis of Pregnancy (ICP)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-01-12 (ESTIMATED); Lead Sponsor Mirum Pharmaceuticals, Inc.." https://clinicaltrials.gov/study/NCT07823127

### January 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Intrahepatic Cholestasis of Pregnancy.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07823127 (MRX-901: An Open-label Study to Assess Safety and Tolerability of Maralixibat in Participants With Intrahepatic Cholestasis of Pregnancy (ICP)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-01-12 (ESTIMATED); Lead Sponsor Mirum Pharmaceuticals, Inc.." https://clinicaltrials.gov/study/NCT07823127

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/maralixibat.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "LIVMARLI® (maralixibat) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/maralixibat

```bibtex
@misc{secapidev_pdufa_maralixibat_20261116,
  title        = {LIVMARLI® (maralixibat) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/maralixibat}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_maralixibat_20261116","title":"LIVMARLI® (maralixibat) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/maralixibat","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
